Expression and prognostic significance of Src family members in renal clear cell carcinoma

British Journal of Cancer

Volumn 107, Issue 5, 2012, Pages 856-863

  Qayyum, T ^a   McArdle, P A ^b   Lamb, G W ^b   Jordan, F ^c   Orange, C ^d   Seywright, M ^d   Horgan, P G ^a   Jones, R J ^e   Oades, G ^b   Aitchison, M A ^b   Edwards, J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d WESTERN INFIRMARY   (United Kingdom)

^e BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

FAK; renal cancer; Src; Src kinase

Indexed keywords

BLK PROTEIN; FGR PROTEIN; FOCAL ADHESION KINASE; HEMATOPOIETIC CELL KINASE; MESSENGER RNA; PROTEIN KINASE FYN; PROTEIN KINASE LCK; PROTEIN KINASE LYN; PROTEIN KINASE P60; PROTEIN KINASE YES; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; CELL MEMBRANE; CELL NUCLEUS; COHORT ANALYSIS; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; CARCINOMA, RENAL CELL; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SRC-FAMILY KINASES;

EID: 84865420832     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.314     Document Type: Article

References (33)

1. Bates RC, Edwards NS, Burns GF, Fisher DE (2001) A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoi-nositide 3-kinase/Akt in colon carcinoma cells. Cancer Res 61(13): 5275-5283 (Pubitemid 32681564)
2. Blaveri E, Simko JP, Korkola JE, Brewer JL, Baehner F, Mehta K, Devries S, Koppie T, Pejavar S, Carroll P, Waldman FM (2005) Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 11(11): 4044-4055 (Pubitemid 40791568)
3. Bolen JB, Veillette A, Schwartz AM, DeSeau V, Rosen N (1987) Activation of pp60c-src protein kinase activity in human colon carcinoma. Proc Natl Acad Sci USA 84(8): 2251-2255 (Pubitemid 17075849)
4. Calalb MB, Polte TR, Hanks SK (1995) Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Mol Cell Biol 15(2): 954-963
5. Calalb MB, Zhang X, Polte TR, Hanks SK (1996) Focal adhesion kinase tyrosine-861 is a major site of phosphorylation by Src. Biochem Biophys Res Commun 228(3): 662-668 (Pubitemid 26421437)
6. Campbell EJ, McDuff E, Tatarov O, Tovey S, Brunton V, Cooke TG, Edwards J (2008) Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer. Br J Cancer 99(11): 1769-1774
7. Choi YL, Bocanegra M, Kwon MJ, Shin YK, Nam SJ, Yang JH, Kao J, Godwin AK, Pollack JR (2010) LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. Cancer Res 70(6): 2296-2306
8. Cooper JA, Howell B (1993) The when and how of Src regulation. Cell 73(6): 1051-1054 (Pubitemid 23180479)
9. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T (2005) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev (1): CD001425
10. Edwards J, Krishna NS, Witton CJ, Bartlett JM (2003) Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res 9(14): 5271-5281 (Pubitemid 37413579)
11. Elsberger B, Fullerton R, Zino S, Jordan F, Mitchell TJ, Brunton VG, Mallon EA, Shiels PG, Edwards J (2010a) Breast cancer patients' clinical outcome measures are associated with Src kinase family member expression. Br J Cancer 103(6): 899-909
12. Elsberger B, Tan BA, Mallon EA, Brunton VG, Edwards J (2010b) Is there an association with phosphorylation and dephosphorylation of Src kinase at tyrosine 530 and breast cancer patient disease-specific survival. Br J Cancer 103(12): 1831-1834
13. Elsberger B, Tan BA, Mitchell TJ, Brown SB, Mallon EA, Tovey SM, Cooke TG, Brunton VG, Edwards J (2009) Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR-and HER2-negative breast cancer patients? Am J Pathol 175(4): 1389-1397
14. Engen JR, Wales TE, Hochrein JM, Meyn III MA, Banu OS, Bahar I, Smithgall TE (2008) Structure and dynamic regulation of Src-family kinases. Cell Mol Life Sci 65(19): 3058-3073
15. Fanning P, Bulovas K, Saini KS, Libertino JA, Joyce AD, Summerhayes IC (1992) Elevated expression of pp60c-src in low grade human bladder carcinoma. Cancer Res 52(6): 1457-1462
16. Fincham VJ, Brunton VG, Frame MC (2000) The SH3 domain directs acto-myosin-dependent targeting of v-Src to focal adhesions via phosphatidylinositol 3-kinase. Mol Cell Biol 20(17): 6518-6536 (Pubitemid 30650238)
17. Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ (2007) Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple- negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 105(3): 319-326 (Pubitemid 47596452)
18. Kirkegaard T, Edwards J, Tovey S, McGlynn LM, Krishna SN, Mukherjee R, Tam L, Munro AF, Dunne B, Bartlett JM (2006) Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 48(7): 787-794 (Pubitemid 43800937)
19. Kopetz S, Shah AN, Gallick GE (2007) Src continues aging: current and future clinical directions. Clin Cancer Res 13(24): 7232-7236
20. Masaki T, Igarashi K, Tokuda M, Yukimasa S, Han F, Jin YJ, Li JQ, Yoneyama H, Uchida N, Fujita J, Yoshiji H, Watanabe S, Kurokohchi K, Kuriyama S (2003) pp60c-src activation in lung adenocarcinoma. Eur J Cancer 39(10): 1447-1455
21. Masaki T, Okada M, Shiratori Y, Rengifo W, Matsumoto K, Maeda S, Kato N, Kanai F, Komatsu Y, Nishioka M, Omata M (1998) pp60c-src activation in hepatocellular carcinoma of humans and LEC rats. Hepatology 27(5): 1257-1264 (Pubitemid 28227852)
22. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20(1): 289-296 (Pubitemid 34032623)
23. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, Mirosevich J, Lee FY, Jove R (2005) Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 65(20): 9185-9189 (Pubitemid 41507982)
24. Qayyum T, Fyffe G, Duncan M, McArdle PA, Hilmy M, Orange C, Halbert G, Seywright M, Horgan PG, Underwood MA, Edwards J (2012) The interrelationships between Src, Cav-1 and RhoGD12 in transitional cell carcinoma of the bladder. Br J Cancer 106(6): 1187-1195
25. Roskoski Jr. R (2005) Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophys Res Commun 331(1): 1-14 (Pubitemid 40545134)
26. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C (2006) Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 24(5): 778-789 (Pubitemid 46622045)
27. Schaller MD, Hildebrand JD, Shannon JD, Fox JW, Vines RR, Parsons JT (1994) Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Mol Cell Biol 14(3): 1680-1688
28. Stadler WM, Huo D, George C, Yang X, Ryan CW, Karrison T, Zimmerman TM, Vogelzang NJ (2003) Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol 170(4 Part 1): 1141-1145 (Pubitemid 37108098)
29. Tatarov O, Mitchell TJ, Seywright M, Leung HY, Brunton VG, Edwards J (2009) SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res 15(10): 3540-3549
30. Thomas S, Overdevest JB, Nitz MD, Williams PD, Owens CR, Sanchez-Carbayo M, Frierson HF, Schwartz MA, Theodorescu D (2011) Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladder cancer. Cancer Res 71(3): 832-841
31. Verbeek BS, Vroom TM, Adriaansen-Slot SS, Ottenhoff-Kalff AE, Geertzema JG, Hennipman A, Rijksen G (1996) c-Src protein expressi on is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 180(4): 383-388 (Pubitemid 27014075)
32. Wilson GR, Cramer A, Welman A, Knox F, Swindell R, Kawakatsu H, Clarke RB, Dive C, Bundred NJ (2006) Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity. Br J Cancer 95(10): 1410-1414 (Pubitemid 44760094)
33. Wu Y, Moissoglu K, Wang H, Wang X, Frierson HF, Schwartz MA, Theodorescu D (2009) Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function. Proc Natl Acad Sci USA 106(14): 5807-5812